Skip to content
OpenCapital
Get started

Beam Therapeutics BEAM EBITDA

EBITDA at other companies

CRISPR Therapeutics logo
CRISPR TherapeuticsCRSP
-$125.93M+12.4%
Cogent Biosciences, Inc. logo
Cogent Biosciences, Inc.COGT
-$102.98M-38.6%
PTC Therapeutics logo
PTC TherapeuticsPTCT
$60.37M-93.8%
Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
——
Arrowhead Research logo
Arrowhead ResearchARWR
——
BridgeBio Pharma logo
BridgeBio PharmaBBIO
——

Other financials

Income statement

See full
Revenue$31.7M+325%
Operating income-$107.2M+10.1%
Net income-$94.3M+12.9%
EPS (diluted)-$0.91+26.0%

Balance sheet

See full
Cash & equivalents$288.3M-45.4%
Total debt$250.8M+58.6%
Total equity$1.2B+3.1%
Total assets$1.5B+0.9%

Cash flow

See full
Operating cash flow-$128.5M-23.7%
CapEx$2.2M-27.2%
Free cash flow-$130.7M-22.2%

Valuation

See full
Market cap$3.51B+24.5%
Enterprise value$3.47B+51.2%
P/S21.4×-23.0×

Profitability

See full
Operating margin-226.6%-90.5pp
Net margin-742.7%—
FCF margin-234%-86.6pp

Returns & leverage

See full
Return on equity-47.1%—
Debt / equity0.2×+0.1×
Current ratio17×+8.2×

Where this comes from

Calculated from Beam Therapeutics’s reported figures.

−$107.2Mebit+
$5.6MDepreciation Depletion & Amortization
=-$101.61M

The official record: Beam Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Beam Therapeutics's ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Beam Therapeutics's EBITDA?
Beam Therapeutics (BEAM) reported EBITDA of -$101.61M in Q1 2026.
How has Beam Therapeutics's EBITDA changed year-over-year?
Beam Therapeutics's EBITDA increased by 10.7% year-over-year, from -$113.76M to -$101.61M.
What is the long-term trend for Beam Therapeutics's EBITDA?
Over 3 years (2021 to 2025), Beam Therapeutics's EBITDA has grown at a -2.1% compound annual growth rate (CAGR), from -$385.01M to -$361.4M.
What does EBITDA mean?
Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.